Medicamen Biotech Limited Asset Resilience Ratio
Medicamen Biotech Limited asset resilience ratio. Medicamen Biotech Limited (MEDICAMEQ) has an Asset Resilience Ratio of 0.99% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See MEDICAMEQ defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Medicamen Biotech Limited (2006–2026)
Asset resilience ratio of Medicamen Biotech Limited from 2006 to 2026. This chart shows how Medicamen Biotech Limited's Asset Resilience Ratio has changed over time. Read Medicamen Biotech Limited balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Medicamen Biotech Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see MEDICAMEQ current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0% |
| Short-term Investments | Rs29.49 Million | 0.99% |
| Total Liquid Assets | Rs29.49 Million | 0.99% |
Asset Resilience Insights
- Limited Liquidity: Medicamen Biotech Limited maintains only 0.99% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Medicamen Biotech Limited Industry Peers by Asset Resilience Ratio
Compare Medicamen Biotech Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Sandoz Group AG
SW:SDZ |
Drug Manufacturers - Specialty & Generic | 7.89% |
|
H Lundbeck A/S
CO:HLUN-B |
Drug Manufacturers - Specialty & Generic | -0.56% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Viyash Scientific Limited
NSE:SEQUENT |
Drug Manufacturers - Specialty & Generic | 0.08% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
Medicamen Biotech Limited Asset Resilience Ratio by Year (2006–2026)
Medicamen Biotech Limited asset resilience ratio by year from 2006 to 2026. The table below shows the annual Asset Resilience Ratio data for Medicamen Biotech Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2026-03-31 | 8.09% | Rs300.77 Million ≈ $3.25 Million |
Rs3.72 Billion ≈ $40.23 Million |
+7.09pp |
| 2025-03-31 | 0.99% | Rs29.49 Million ≈ $318.96K |
Rs2.97 Billion ≈ $32.11 Million |
-3.73pp |
| 2024-03-31 | 4.73% | Rs139.20 Million ≈ $1.51 Million |
Rs2.95 Billion ≈ $31.85 Million |
-1.80pp |
| 2023-03-31 | 6.53% | Rs181.86 Million ≈ $1.97 Million |
Rs2.79 Billion ≈ $30.12 Million |
+5.21pp |
| 2022-03-31 | 1.32% | Rs29.89 Million ≈ $323.25K |
Rs2.26 Billion ≈ $24.41 Million |
+1.31pp |
| 2021-03-31 | 0.02% | Rs361.20K ≈ $3.91K |
Rs1.94 Billion ≈ $20.98 Million |
+0.01pp |
| 2020-03-31 | 0.01% | Rs216.77K ≈ $2.34K |
Rs1.81 Billion ≈ $19.61 Million |
-5.08pp |
| 2019-03-31 | 5.09% | Rs69.51 Million ≈ $751.77K |
Rs1.37 Billion ≈ $14.77 Million |
+5.03pp |
| 2018-03-31 | 0.06% | Rs700.00K ≈ $7.57K |
Rs1.18 Billion ≈ $12.71 Million |
-0.04pp |
| 2017-03-31 | 0.10% | Rs700.00K ≈ $7.57K |
Rs734.01 Million ≈ $7.94 Million |
+0.06pp |
| 2016-03-31 | 0.03% | Rs200.00K ≈ $2.16K |
Rs600.18 Million ≈ $6.49 Million |
+0.00pp |
| 2015-03-31 | 0.03% | Rs200.00K ≈ $2.16K |
Rs686.63 Million ≈ $7.43 Million |
0.00pp |
| 2014-03-31 | 0.03% | Rs200.00K ≈ $2.16K |
Rs645.79 Million ≈ $6.98 Million |
+0.00pp |
| 2013-03-31 | 0.03% | Rs200.00K ≈ $2.16K |
Rs652.34 Million ≈ $7.05 Million |
+0.00pp |
| 2012-03-31 | 0.03% | Rs200.00K ≈ $2.16K |
Rs689.07 Million ≈ $7.45 Million |
-0.33pp |
| 2008-03-31 | 0.36% | Rs1.85 Million ≈ $20.06K |
Rs517.72 Million ≈ $5.60 Million |
-0.29pp |
| 2007-03-31 | 0.65% | Rs3.00 Million ≈ $32.44K |
Rs464.17 Million ≈ $5.02 Million |
+0.45pp |
| 2006-03-31 | 0.19% | Rs652.49K ≈ $7.06K |
Rs338.18 Million ≈ $3.66 Million |
-- |
About Medicamen Biotech Limited
Medicamen Biotech Limited, a pharmaceutical company, research, develops, manufactures, markets, and sells pharmaceutical formulations in India and internationally. The company provides tablets, capsules, dry syrups, oral liquids, ointments, and other pharmaceutical dosage forms. Its products are used in therapeutic areas comprising cancer care, cardiology, CNS, diabetology, anti-infective, anti-m… Read more